Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Get Free Report) was up 8.2% on Tuesday . The company traded as high as $2.77 and last traded at $2.77. Approximately 84,104 shares traded hands during trading, a decline of 89% from the average daily volume of 779,414 shares. The stock had previously closed at $2.5610.
Analysts Set New Price Targets
Several analysts have issued reports on CURLF shares. Canaccord Genuity Group raised Curaleaf to a “strong-buy” rating in a research note on Thursday, October 9th. ATB Capital raised shares of Curaleaf to an “outperform” rating in a research note on Tuesday, December 2nd. Finally, Atb Cap Markets upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. Based on data from MarketBeat.com, Curaleaf currently has an average rating of “Strong Buy”.
Read Our Latest Stock Report on CURLF
Curaleaf Trading Up 6.3%
Curaleaf (OTCMKTS:CURLF – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. Sell-side analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.
About Curaleaf
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
- Five stocks we like better than Curaleaf
- When to Sell a Stock for Profit or Loss
- Big Blue’s Big Bet: IBM Buys AI Nervous System for $11B
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Carvana Soars Over 10,000% From Lows—Now It’s in the S&P 500
- 5 discounted opportunities for dividend growth investors
- UiPath Surges on Earnings: Should Investors Chase the Momentum?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
